What is Entia Biosciences, Inc. (ERGO) stock price today?

Entia Biosciences, Inc. (ERGO) is currently trading at $0.00.

What is ERGO return on equity (ROE)?

Entia Biosciences, Inc.'s return on equity (ROE) is 50.00%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.

What is Entia Biosciences, Inc.'s market cap?

Entia Biosciences, Inc. has a market capitalization of $6732.

OTC · Medical - Pharmaceuticals

Entia Biosciences, Inc. (ERGO) Stock

$0.00 OTC: ERGO Healthcare

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States.

Valuation

Metric	Value
Price	$0.00
Market Cap	$6732
P/E Ratio	0.00
P/B Ratio	0.00
P/S Ratio	0.03
EPS (TTM)	$-0.05
52-Week High	$0.04
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	50.00%
ROA	-335.35%
ROCE	70.05%
Gross Margin	65.53%
Operating Margin	-439.75%
Net Margin	-554.75%
Debt/Equity	-0.50
Current Ratio	0.11

Annual Financials (USD)

Metric	2012	2013	2014	2015	2016
Revenue	$0	$0	$1.0M	$0	$0
Operating Profit	$-1.0M	$-3.0M	$-2.0M	$-2.0M	$-1.0M
Net Profit	$-2.0M	$-3.0M	$-3.0M	$-2.0M	$-1.0M
EPS	$-0.21	$-0.43	$-0.28	$-0.10	$-0.05
Op Margin	-292.6%	-852.0%	-269.8%	-552.3%	-439.8%

Balance Sheet (USD)

Metric	2012	2013	2014	2015	2016
Total Assets	$0	$1.0M	$1.0M	$0	$0
Total Liabilities	$1.0M	$2.0M	$1.0M	$1.0M	$2.0M
Cash	$0	$0	$0	$0	$0
Borrowings	$0	$0	$0	$0	$1.0M

Cash Flow (USD)

Metric	2012	2013	2014	2015	2016
Operating Cash Flow	$0	$-1.0M	$-1.0M	$-1.0M	$-1.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$0	$1.0M	$0	$1.0M	$0
Net Cash Flow	$0	$0	$0	$0	$0
Free Cash Flow	$0	$-1.0M	$-1.0M	$-1.0M	$-1.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-0.75
FCF Yield	-10728.09%
Quick Ratio	0.08
Interest Coverage	-13.98
Return 1Y	0.00%
Return 3Y	0.00%
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AVXTAVAX Technologies, Inc.	$0.00	—	0.00	$6894	0.00%
BNGIBangi Inc.	$0.00	—	0.00	$5254	0.00%
BTAXBiostax Corp.	$0.00	—	0.00	$15743	0.00%
BTTXBetter Therapeutics, Inc.	$0.00	—	0.00	$5452	0.00%
DNAGDNAPrint Genomics, Inc.	$0.00	—	—	$12892	0.00%

About Entia Biosciences, Inc.

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseases. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical food, nutraceuticals, cosmetics, and other products. In addition, the company offers beauty products under the GROH brand name. It markets its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was incorporated in 2007 and is headquartered in Sherwood, Oregon.

Entia Biosciences, Inc. (ERGO) stock trades at $0.00 with a market capitalization of $6732. The stock is valued at price-to-book of 0.00, price-to-sales of 0.03. Over the past 52 weeks the stock has ranged between $0.00 and $0.04, and currently trades 100.0% below its 52-week high.

On profitability, Entia Biosciences, Inc. generates a return on equity (ROE) of 50.00% (not meaningful, as shareholders' equity is negative), return on capital employed of 70.05%, an operating margin of -439.75%, a net profit margin of -554.75%.

Official website: www.roxanaradu.com